GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals

By Andrew Karpan · July 11, 2024, 5:19 PM EDT

A GlaxoSmithKline lawyer has urged a Delaware federal judge to make up his mind about a nearly $400 million patent case against Teva Pharmaceuticals in light of unrelated "opioid-related cases" that the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Letter

Case Information

Case Title

GlaxoSmithKline LLC et al v. Teva Pharmaceuticals USA Inc.

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

July 03, 2014

Recent Articles By Andrew

November 12, 2024
GOP Reps. Propose Another Bill On TRIPS Waivers
October 23, 2024
Court Denies Fees In 'Objectively Specious' Trade Secrets Suit
October 02, 2024
Avadel Tells Fed. Circ. It Should Be Free To Test Sleep Drug
September 26, 2024
2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
September 09, 2024
Purdue Sees Another OxyContin Patent Axed
September 05, 2024
Nvidia, Microsoft Face Patent, Cartel Allegations In Texas Suit
August 09, 2024
Valeant's Legal Gripe A Total 'Nothingburger,' Justices Told
July 09, 2024
South Africa Drops J&J Probe After TB Drug Price Cuts
June 26, 2024
Ga. High Court Told To Skip Inventor's 'Clerical Mistake' Fight
June 13, 2024
IP Forecast: Cooley Atty Faces DQ Bid Over Past Patent Work